首页 > 分享 > 肠道菌群与肠易激综合征相关研究进展

肠道菌群与肠易激综合征相关研究进展

萌宠菠菠乐园
2024-09-15 23:51

摘要:肠易激综合征(irritable bowel syndrome,IBS)是一种功能性肠病,目前已有研究表明IBS的致病机制、症状的产生和持续时间可能与肠道菌群失调有关,且不同IBS亚型患者体内的肠道菌群种类有差异。IBS的发病机制尚不完全清楚,临床表现存在较大的个体差异。IBS的诊断和治疗尚未形成统一的标准。但已经有较多研究提示IBS可能与胃肠道动力、内脏高敏感性、肠道免疫反应和模式识别受体等密切相关,并且可以通过益生菌、益生元、抗生素、粪菌移植和饮食习惯等调节肠道菌群的失调,从而改善IBS的症状。这也为未来治疗IBS提供了新的思路。本文就肠道菌群的概况、IBS患者肠道菌群的特点、肠道菌群失衡导致IBS发病的可能机制以及IBS肠道菌群的相关治疗方法的研究进展作一综述。

Abstract:Irritable bowel syndrome (IBS) is a kind of functional bowel diseases. The pathogenesis, symptoms and persistence of IBS may be related to intestinal flora imbalance, and the types of intestinal flora in different IBS subtypes are different. At present, the pathogenesis of IBS is still unclear, and the clinical manifestations are quite individually different. There have not yet been unified standards for the diagnosis and treatment of IBS. However, many studies suggested that IBS may be closely related to gastrointestinal motility, visceral hypersensitivity, intestinal immune response and pattern recognition receptors, and can be improved through regulation of intestinal flora imbalance by probiotics, prebiotics, antibiotics, fecal bacteria transplantation and dietary habits, which provides a new idea for the future treatment of IBS. This article reviewed the progress in researches on the overview and characteristics intestinal flora in IBS patients, the possible mechanisms of intestinal flora imbalance leading to IBS, and the treatment of IBS intestinal flora.

[1]

陈立亚, 刘畅, 汪芳裕.肠易激综合征与肠道微生态及脑-肠轴关系的研究进展[J].胃肠病学和肝病学杂志, 2017,26(5):491-495.CHEN Liya, LIU Chang, WANG Fangyu.Research progress of the relationship of gut microbiota, gut-brain axis with irritable bowel syndrome[J].Chin J Gastroenterol Hepatol, 2017,26(5):491-495.(in Chinese)

[2]

章菲菲.肠道菌群失衡与肠易激综合征[J].上海医药, 2016,37(19):3-8.ZHANG Feifei.Irritable bowel syndrome and gut microbiota dysbiosis[J].Shanghai Med Pharm J, 2016,37(19):3-8.(in Chinese)

[3]

Rajili′-Stojanovi′ M, Heilig HG, Tims S, et al.Long-term monitoring of the human intestinal microbiota composition[J].Environ Microbiol, 2012.doi:10.1111/1462-2920.12023.

[4]

Caporaso JG, Lauber CL, Costello EK, et al.Moving pictures of the human microbiome[J].Genome Biol, 2011,12(5):R50.

[5]

江月斐, 劳绍贤, 邝枣园, 等.腹泻型肠易激综合征脾胃湿热证肠道菌群的变化[J].中国中西医结合杂志, 2006,26(3):218-220.JIANG Yuefei, LAO Shaoxian, KUANG Zaoyuan, et al.Preliminary study on intestinal flora in diarrhea type irritable bowel syndrome with Pi-wei dampness-heat syndrome[J].Chin J Integr Trad West Med, 2006,26(3):218-220.(in Chinese)

[6]

Malinen E, Rinttil T, Kajander K, et al.Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR[J].Am J Gastroenterol, 2005,100(2):373-382.

[7]

Carroll IM, Ringelkulka T, Siddle JP, et al.Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome[J].Neurogastroent Motil, 2012,24(6):521-530..

[8]

胡建广, 钟小仕, 闫静, 等.高通量测序分析老年血液透析患者肠道菌群的改变[J].中国中西医结合肾病杂志, 2017,18(2):127-131.HU Jianguang, ZHONG Xiaoshi, YAN Jing, et al.Evaluation of intestinal microflora by high-throughput gene sequencing in elderly HD patients[J].Chin J Integr Trad West Nephrol, 2017,18(2):127-131.(in Chinese)

[9]

徐孝平, 徐剑钦, 黄俊杰, 等.WHBE兔与日本大耳白兔腹泻型肠易激综合征模型的肠道菌群研究[J].中国实验动物学报, 2018,26(2):165-173.(in Chinese) XU Xiaoping, XU Jianqin, HUANG Junjie, et al.Characterization of intestinal microflora in WHBE rabbit and Japanese white rabbit models of diarrhea-predominant irritable bowel syndrome[J].Acta Lab Anim Sci Sin, 2018,26(2):165-173.

[10]

李刚平.中国腹泻型肠易激综合征患者肠道菌群的特点研究[D].武汉:华中科技大学, 2015.LI Gangping.Characteristics of gut microbiota in Chinese patients with irritable bowel syndrome with diarrhea[D].Wuhan:Huazhong University of Science and Technology, 2015.

[11]

Martens EC, Koropatkin NM, Smith TJ, et al.Complex glycan catabolism by the human gut microbiota:the Bacteroidetes Sus-like paradigm[J].J Biol Chem, 2009,284(37):24673-24677.

[12]

胡乐义.肠易激综合征患者肠道菌群变化及抗生素利福昔明的影响[D].合肥:安徽医科大学, 2012.HU Leyi.The changes of intestinal microflora in patients with irritable bowel syndrome and the effects of antibiotic rifaximin[D].Hefei:Anhui Medical University, 2012.(in Chinese)

[13]

薛润国, 宣建新, 崔冰, 等.肠易激综合征(IBS)患者肠道菌群变化情况其意义研究[J].世界最新医学信息文摘, 2017,17(43):110-111.

[14]

计敏, 黄华, 蓝显明, 等.不同亚型肠易激综合征患者肠道菌群改变的观察[J].临床消化病杂志, 2016,28(2):103-106.JI Min, HUANG Hua, LAN Xianming, et al.Changes of intestinal microflora in different irritable bowel syndrome subtypes[J].Chin J Clin Gastroenterol, 2016,28(2):103-106.(in Chinese)

[15]

张莉.肠易激综合征患者肠道菌群定量分析与意义[J].中国医药导报, 2008,5(19):94-96.ZHANG Li.Significance of intestinal tract normal bacteria flora quantitative analysis of IBS sufferers[J].China Med Herald, 2008,5(19):94-96.(in Chinese)

[16]

Beerens H.An elective and selective medium for Bifidobacterium spp.[J].Lett Appl Microbiol, 2008,11(3):155-157.

[17]

Carroll IM, Chang YH, Park J, et al.Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome[J].Gut Pathog, 2010,2(1):19.

[18]

Chassard C, Dapoigny M, Scott KP, et al.Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome[J].Aliment Pharmacol Ther, 2012,35(7):828-838.

[19]

Sheikh Sajjadieh MR, Kuznetsova LV, Bojenko VB.Dysbiosis in ukrainian children with irritable bowel syndrome affected by natural radiation[J].Iran J Pediatr, 2012,22(3):364-368.

[20]

Kerckhoffs AP, Samsom M, van der Rest ME, et al.Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients[J].World J Gastroenterol, 2009,15(23):2887-2892.

[21]

Salonen A, de Vos WM, Palva A.Gastrointestinal microbiota in irritable bowel syndrome:present state and perspectives[J].Microbiology, 2010,156(Pt 11):3205-3215.

[22]

Rigsbee L, Agans R, Shankar V, et al.Quantitative profiling of gut microbiota of children with diarrhea-predominant irritable bowel syndrome[J].Am J Gastroenterol, 2012,107(11):1740-1751.

[23]

Rajili′-Stojanovi′ M, Biagi E, Heilig HG, et al.Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome[J].Gastroenterology, 2011,141(5):1792-1801.

[24]

Tana C, Umesaki Y, Imaoka A, et al.Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome[J].Neurogastroent Motil, 2010,22(5):512-519.

[25]

Fukuda S, Toh H, Hase K, et al.Bifidobacteria can protect from enteropathogenic infection through production of acetate[J].Nature, 2011,469(7331):543-547.

[26]

Jalanka-Tuovinen J, Salojrvi J, Salonen A, et al.Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome[J].Gut, 2014,63(11):1737-1745.

[27]

Durbán A, Abellán JJ, Jiménez-Hernández N, et al.Structural alterations of faecal and mucosa-associated bacterial communities in irritable bowel syndrome[J].Environ Microbiol Rep, 2012,4(2):242-247.

[28]

Distrutti E, Monaldi L, Ricci P, et al.Gut microbiota role in irritable bowel syndrome:new therapeutic strategies[J].World J Gastroenterol, 2016,22(7):2219-2241.

[29]

Lindfors P, Hans Trnblom, Sadik R, et al.Effects on gastrointestinal transit and antroduodenojejunal manometry after gut-directed hypnotherapy in irritable bowel syndrome(IBS)[J].Scand J Gastroenterol, 2012,47(12):1480-1487.

[30]

Ammoscato F, Scirocco A, Altomare A, et al.Lactobacillus rhamnosus protects human colonic muscle from pathogen lipopolysaccharide-induced damage[J].Neurogastroenterol Motil, 2013,25(12):984-e777.

[31]

Aguilera M, Cerdà-Cuéllar M, Martínez V.Antibiotic-induced dysbiosis alters host-bacterial interactions and leads to colonic sensory and motor changes in mice[J].Gut Microbes, 2015,6(1):10-23.

[32]

Aguilera M, Vergara P, Martínez V.Stress and antibiotics alter luminal and wall-adhered microbiota and enhance the local expression of visceral sensory-related systems in mice[J].Neurogastroenterol Motil, 2013,25(8):e515-e529.

[33]

Perez-Burgos A, Wang L, McVey Neufeld KA.The TRPV1 channel in rodents is a major target for antinociceptive effect of the probiotic Lactobacillus reuteri DSM 17938[J].J Physiol, 2015,593(17):3943-3957.

[34]

Rhee SH, Pothoulakis C, Mayer EA.Principles and clinical implications of the brain-gut-enteric microbiota axis[J].Nat Rev Gastroenterol Hepatol, 2009,6(5):306-314.

[35]

McClure R, Massari P.TLR-dependent human mucosal epithelial cell responses to microbial pathogens[J].Front Immunol, 2014,5:386.

[36]

Perez-Chanona E, Mühlbauer M, Jobin C.The microbiota protects against ischemia/reperfusion-induced intestinal injury through nucleotide-binding oligomerization domain-containing protein 2(NOD2) signaling[J].Am J Pathol, 2014,184(11):2965-2975.

[37]

Mu C, Yang Y, Zhu W.Crosstalk between the immune receptors and gut microbiota[J].Curr Protein Pept Sci, 2015,16(7):622-631.

[38]

Hayashi H, Sakamoto M, Benno Y.Phylogenetic analysis of the human gut microbiota using 16S rDNA clone libraries and strictly anaerobic culture-based methods[J].Microbiol Immunol, 2002,46(8):535-548.

[39]

D′Aversa F, Tortora A, Ianiro G, et al.Gut microbiota and metabolic syndrome[J].Int Emerg Med, 2013,8(Suppl 1):11-15.

[40]

Moayyedi P, Ford AC, Talley NJ, et al.The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review[J].Gut, 2010,59(3):325-332.

[41]

Lorenzo-Zúiga V, Llop E, Suárez C, et al.I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life[J].World J Gastroenterol, 2014,20(26):8709-8716.

[42]

Clarke G, Cryan JF, Dinan TG, et al.Review article:probiotics for the treatment of irritable bowel syndrome-focus on lactic acid bacteria[J].Aliment Pharmacol Ther, 2012,35(4):403-413.

[43]

de Jesus Raposo MF, de Morais AM, de Morais RM.Emergent sources of prebiotics:seaweeds and microalgae[J].Mar Drugs, 2016,14(2).pii:E27.

[44]

Layer P, Andresen V.Review article:rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers′ diarrhoea[J].Aliment Pharmacol Ther, 2010,31(11):1155-1164.

[45]

赵萌, 李岩.以肠道菌群为靶点治疗肠易激综合征的研究进展[J].胃肠病学和肝病学杂志, 2017,26(5):487-490.ZHAO Meng, LI Yan.Progress of intestinal flora in treatment of irritable bowel syndrome[J].Chin J Gastroenterol Hepatol.2017,26(5):487-490.(in Chinese)

[46]

Pinn DM, Aroniadis OC, Brandt LJ.Is fecal microbiota transplantation the answer for irritable bowel syndrome? A single-center experience[J].Am J Gastroenterol, 2014,109(11):1831-1832.

[47]

Furnari M, Savarino E, Bruzzone L, et al.Reassessment of the role of methane production between irritable bowel syndrome and functional constipation[J].J Gastrointestin Liver Dis, 2012,21(2):157.